Erlotinib (Erlotinib) (Tablet) (Erlotinib)


Indications and Reactions:

Role Indications Reactions
Primary
Non-small Cell Lung Cancer 44.3%
Lung Adenocarcinoma 13.7%
Pancreatic Carcinoma Metastatic 5.9%
Lung Neoplasm Malignant 5.7%
Pancreatic Carcinoma 5.3%
Oesophageal Carcinoma 4.6%
Adenocarcinoma Pancreas 3.1%
Lung Squamous Cell Carcinoma Stage Unspecified 2.5%
Hepatic Neoplasm Malignant 2.2%
Ovarian Cancer 2.0%
Colorectal Cancer Metastatic 1.9%
Head And Neck Cancer 1.7%
Non-small Cell Lung Cancer Metastatic 1.2%
Glioblastoma Multiforme 1.1%
Product Used For Unknown Indication 1.0%
Glioblastoma 0.9%
Bile Duct Cancer 0.8%
Colorectal Cancer 0.7%
Drug Use For Unknown Indication 0.6%
Lung Cancer Metastatic 0.6%
Vomiting 11.1%
Rash 10.9%
Respiratory Failure 8.0%
Pneumonia 7.6%
Pulmonary Embolism 6.9%
White Blood Cell Count Decreased 6.5%
Pyrexia 4.9%
Weight Decreased 4.7%
Death 4.5%
Stomatitis 4.5%
Pleural Effusion 4.2%
Thrombocytopenia 4.0%
Malignant Neoplasm Progression 3.6%
Anaemia 3.3%
Neutropenia 2.9%
Pneumothorax 2.9%
Urinary Tract Infection 2.9%
White Blood Cell Count Increased 2.4%
Sudden Death 2.2%
Nausea 2.0%
Secondary
Hepatic Neoplasm Malignant 100.0%
Vomiting 100.0%

Drug Data